Form 4: Bausch & Lomb Director Karen Ling Receives Annual Equity Grant

Bausch & Lomb Corp. Director Karen Ling was granted 20,338 restricted share units as part of her annual compensation, increasing her direct beneficial ownership to 37,676 common shares.

Summary

• Karen Ling, a Director of Bausch & Lomb Corp. (BLCO), received an annual grant of 20,338 restricted share units (RSUs).
• The transaction occurred on May 27, 2025, with a reported price of $0, indicating a grant rather than a purchase.
• These RSUs were granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
• Upon vesting, these RSUs will be settled in common shares, no par value, of Bausch + Lomb Corporation.
• The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.
• Following this transaction, Ms. Ling's direct beneficial ownership of Bausch & Lomb common shares increased to 37,676.

Sentiment

Score: 7

Explanation: The filing reports a standard annual grant of restricted share units to a non-employee director, which is a routine compensation practice and generally viewed as neutral to slightly positive as it aligns director incentives with shareholder interests.

Positives

• The grant of RSUs aligns the director's interests with shareholders, as the value of the compensation is tied to the company's stock performance.
• This is a standard compensation practice for non-employee directors, indicating continuity in corporate governance.

Future Outlook

The 20,338 restricted share units granted to Director Karen Ling are scheduled to vest immediately prior to the next annual meeting of shareholders, at which point they will be settled in common shares of Bausch + Lomb Corporation.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation. Such equity grants are a common practice across publicly traded companies in various industries, including healthcare and pharmaceuticals, to align the interests of non-employee directors with those of shareholders.

Comparison to Industry Standards

• Granting restricted share units (RSUs) to non-employee directors is a widely adopted compensation practice in publicly traded companies, including those in the healthcare and medical device sectors, such as Johnson & Johnson, Medtronic, and Abbott Laboratories.
• The structure of tying director compensation to equity performance through RSUs is consistent with global corporate governance benchmarks, aiming to incentivize long-term value creation.
• While the specific number of units granted (20,338) would typically be benchmarked against peer companies of similar market capitalization and industry focus, this document does not provide comparative data to assess if this grant size is above, below, or in line with industry averages for a director at Bausch & Lomb's peer group.

Corporate Governance

Related Party Transactions

• Grant of 20,338 restricted share units to Karen Ling, a non-employee director, as part of her annual compensation under the company's incentive plan.

Stakeholder Impact

• Shareholders: The equity grant to a director further aligns their financial interests with the long-term performance of the company's stock, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this specific filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this specific filing.

Next Steps

• Vesting of the 20,338 restricted share units immediately prior to the next annual meeting of shareholders.
• Settlement of vested RSUs into common shares of Bausch + Lomb Corporation.

Key Dates

Keywords

Bausch & Lomb, BLCO, Form 4, SEC filing, Restricted Share Units, RSU grant, Director compensation, Insider transaction, Equity compensation, Corporate governance